Date: 2015-02-27
Type of information: Collaboration agreement
Compound: T cell receptor (TCR) and chimeric antigen receptor (CAR) product candidates
Company: Kite Pharma (USA - CA) National Cancer Institute (USA)
Therapeutic area: Cancer - Oncology
Type agreement: collaboration R&D
Action mechanism: cell therapy/gene therapy/CAR-T cell therapy/immunotherapy product
Disease: solid tumors
Details: * On February 27, 2015, Kite Pharma, a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy (eACT™) products for the treatment of cancer, announced that the Company has amended its Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI). The amendment will encompass emerging areas of research in the immune response to tumor neo-antigens, truly tumor-specific antigens generated as tumors accumulate genetic mutations. In addition, new T cell receptor (TCR) and new chimeric antigen receptor (CAR) product candidates targeting solid tumors have been added to the collaboration. The amendment broadens Kite's ongoing research collaboration with the Surgery Branch at the NCI, led by Steven A. Rosenberg, M.D., Ph.D. and provides additional product candidates for Kite's growing pipeline.Under Kite's amended agreement with the NCI, the additional programs will encompass: - Methods of rapidly identifying and developing TCR product candidates targeted against neo-antigens. - Optimizing new methods to manufacture this new class of individualized therapies. - Developing additional TCR product candidates retrovirally engineered to target tumor antigens, including for the treatment of colorectal and lung cancers.
Financial terms:
Latest news:
